LPA
LPA (Apolipoprotein(a)) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma.
Overview
Apo(a) is the main constituent of lipoprotein(a) (Lp(a)). It has serine proteinase activity and is able of autoproteolysis. Inhibits tissue-type plasminogen activator 1.
Open Targets scores its association with cancer at 0.54 (direct and indirect evidence; datatypes literature 0.87, genetic association 0.63, somatic mutation 0.37). IntOGen calls it a driver in 1 cohort (0 activating, 1 loss-of-function), covering Pancreatic Adenocarcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · LPA (Apolipoprotein(a)) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma.
- 1 · What it is
LPA (Apolipoprotein(a)) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma.
- 2 · What goes wrong in cancer
Apo(a) is the main constituent of lipoprotein(a) (Lp(a)). It has serine proteinase activity and is able of autoproteolysis.
- 3 · How drugs use it
No product in this corpus aims at LPA yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:6667 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P08519 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000198670 (association with cancer (MONDO_0004992) 0.54; (GraphQL API, CC0)); IntOGen LPA (driver in 1 cohort (Act 0, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Apo(a) is the main constituent of lipoprotein(a) (Lp(a)). It has serine proteinase activity and is able of autoproteolysis. Inhibits tissue-type plasminogen activator 1. Lp(a) may be a ligand for megalin/Gp 330. Locus 6q25.3-q26 (HGNC).
- Pancreatic ductal adenocarcinoma: IntOGen driver in 1 cohort (PAAD)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it a loss-of-function (LoF) driver in 1 cohort. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"LPA" OR ABSTRACT:"LPA" OR TITLE:"lipoprotein a" OR ABSTRACT:"lipoprotein a" OR TITLE:"Apolipoprotein a" OR ABSTRACT:"Apolipoprotein a" OR TITLE:"Lp a" OR ABSTRACT:"Lp a") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about LPA, not a curated reading list.